KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short-term Investments: 2013-2017

Historic Short-term Investments for Travere Therapeutics (TVTX) over the last 5 years, with Dec 2017 value amounting to $201.2 million.

  • Travere Therapeutics' Short-term Investments fell 19.51% to $166.4 million in Q2 2018 from the same period last year, while for Jun 2018 it was $166.4 million, marking a year-over-year decrease of 19.51%. This contributed to the annual value of $201.2 million for FY2017, which is 6.35% down from last year.
  • Per Travere Therapeutics' latest filing, its Short-term Investments stood at $201.2 million for FY2017, which was down 6.35% from $214.9 million recorded in FY2016.
  • Over the past 5 years, Travere Therapeutics' Short-term Investments peaked at $214.9 million during FY2016, and registered a low of $132,994 during FY2013.
  • For the 3-year period, Travere Therapeutics' Short-term Investments averaged around $202.6 million, with its median value being $201.2 million (2017).
  • Its Short-term Investments has fluctuated over the past 5 years, first soared by 7,085.29% in 2014, then fell by 6.35% in 2017.
  • Over the past 5 years, Travere Therapeutics' Short-term Investments (Yearly) stood at $132,994 in 2013, then skyrocketed by 7,085.29% to $9.6 million in 2014, then soared by 1,907.11% to $191.8 million in 2015, then rose by 12.03% to $214.9 million in 2016, then decreased by 6.35% to $201.2 million in 2017.